COMBINATION OF SIROSINGOPIN AND MITOCHONDRIAL INHIBITORS FOR TREATMENT OF CANCER AND FOR IMMUNOSUPPRESSION Russian patent published in 2016 - IPC A61K31/155 A61K31/35 A61K31/4745 A61K31/625 A61P35/00 A61P37/00 

FIELD: medicine.

SUBSTANCE: group of inventions is related to medicine, pharmacology, pharmaceutics, and involves a pharmaceutical composition and combination of sirosingopin (SS) and mitochondrial inhibitor (MI), where the said mitochondrial inhibitor represents metformin or fenformin. Ratio of the amount of (wt/wt) CC and MI can range from 1 to 10-1 to 1000. This combination can be used in treating such types of cancer as carcinoma, sarcoma, leukaemia, myeloma, lymphoma, various types of cancer of the nervous system or autoimmune diseases of skin, nervous system, connective tissue, muscles, blood, bone tissue and internal organs, as immunosuppressive therapy. Group of inventions also includes the method of determining if the cancer cell is sensitive to the SS. For this purpose, (a) a suspension of single cells cultivated cancer cells in acceptable media is received; (b) the cancer cell is incubated with SS; (c) the cancer cell obtained at step (b) is incubated with positively charged fluorescent dye; (d) the fluorescence excited intensity is measured; and (e) fluorescence intensity, measured at step (d) is compared with the intensity of fluorescence of the cancer cell to be incubated only with positively charged fluorescent dye. Relative increase in fluorescence intensity of cancer cells, preliminary incubated with SS, means that cells are sensitive to treatment with SS. Group of inventions also includes a method of treating cancer or autoimmune disease by administration of a combination or a composition of SS and the said MI to a warm-blooded animal in the amount effective with respect to the aforementioned disease.

EFFECT: said combination and composition provide a synergetic effect when used regarding the aforementioned disorders, the prognosis of which, in its turn, can be provided for implementation of the above method for prognosis of cancer cell sensitivity to SS.

14 cl, 12 dwg, 1 ex, 1 tbl